At a glance
ClinicalIndex Comparison Record- ✓Females at least 50 years of age
- ✓Unifocal cT1N0 breast cancer on mammography, ultrasound and MRI
- ✓Indication for endocrine therapy per Dutch National Oncoline Guidelines or hospital protocols
- ✓Bloom-Richardson grade 1 or 2
- ✕Legal incapacity
- ✕BRCA1, BRCA2 or CHEK2 gene mutation
- ✕Distant metastasis
- ✕Previous history of breast cancer or DCIS
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients
In Brief
A clinical study evaluating Single dose ablative radiotherapy for Breast Cancer. Currently recruiting, targeting 100 participants across 7 sites in 2 countries.
Detailed Summary
In this ABLATIVE-2 trial, low-risk breast cancer patients will be treated with MRI-guided single dose preoperative partial breast radiotherapy to assess the rate of pathologic complete response after an interval of six to twelve months between radiotherapy and surgery. Response monitoring will be assessed using MRI and markers in blood and tumor tissue to enable prediction of pathologic response.
Study Details
Timeline
Interventions
Patients will receive a single dose of 20Gy/15Gy on the gross tumor volume and clinical tumor volume respectively, in the context of pre-operative partial breast irradiation